3mtf Citations

A new class of small molecule inhibitor of BMP signaling.

Abstract

Growth factor signaling pathways are tightly regulated by phosphorylation and include many important kinase targets of interest for drug discovery. Small molecule inhibitors of the bone morphogenetic protein (BMP) receptor kinase ALK2 (ACVR1) are needed urgently to treat the progressively debilitating musculoskeletal disease fibrodysplasia ossificans progressiva (FOP). Dorsomorphin analogues, first identified in zebrafish, remain the only BMP inhibitor chemotype reported to date. By screening an assay panel of 250 recombinant human kinases we identified a highly selective 2-aminopyridine-based inhibitor K02288 with in vitro activity against ALK2 at low nanomolar concentrations similar to the current lead compound LDN-193189. K02288 specifically inhibited the BMP-induced Smad pathway without affecting TGF-β signaling and induced dorsalization of zebrafish embryos. Comparison of the crystal structures of ALK2 with K02288 and LDN-193189 revealed additional contacts in the K02288 complex affording improved shape complementarity and identified the exposed phenol group for further optimization of pharmacokinetics. The discovery of a new chemical series provides an independent pharmacological tool to investigate BMP signaling and offers multiple opportunities for pre-clinical development.

Articles - 3mtf mentioned but not cited (10)

  1. A new class of small molecule inhibitor of BMP signaling. Sanvitale CE, Kerr G, Chaikuad A, Ramel MC, Mohedas AH, Reichert S, Wang Y, Triffitt JT, Cuny GD, Yu PB, Hill CS, Bullock AN. PLoS One 8 e62721 (2013)
  2. Development of an ALK2-biased BMP type I receptor kinase inhibitor. Mohedas AH, Xing X, Armstrong KA, Bullock AN, Cuny GD, Yu PB. ACS Chem Biol 8 1291-1302 (2013)
  3. A small molecule targeting ALK1 prevents Notch cooperativity and inhibits functional angiogenesis. Kerr G, Sheldon H, Chaikuad A, Alfano I, von Delft F, Bullock AN, Harris AL. Angiogenesis 18 209-217 (2015)
  4. ACVR1 p.Q207E causes classic fibrodysplasia ossificans progressiva and is functionally distinct from the engineered constitutively active ACVR1 p.Q207D variant. Haupt J, Deichsel A, Stange K, Ast C, Bocciardi R, Ravazzolo R, Di Rocco M, Ferrari P, Landi A, Kaplan FS, Shore EM, Reissner C, Seemann P. Hum Mol Genet 23 5364-5377 (2014)
  5. Identification of gefitinib off-targets using a structure-based systems biology approach; their validation with reverse docking and retrospective data mining. Verma N, Rai AK, Kaushik V, Brünnert D, Chahar KR, Pandey J, Goyal P. Sci Rep 6 33949 (2016)
  6. Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity. Alsamarah A, LaCuran AE, Oelschlaeger P, Hao J, Luo Y. PLoS One 10 e0132221 (2015)
  7. In Silico Investigation of the Anti-Tumor Mechanisms of Epigallocatechin-3-Gallate. Wang W, Xiong X, Li X, Zhang Q, Yang W, Du L. Molecules 24 E1445 (2019)
  8. Structural basis for ALK2/BMPR2 receptor complex signaling through kinase domain oligomerization. Agnew C, Ayaz P, Kashima R, Loving HS, Ghatpande P, Kung JE, Underbakke ES, Shan Y, Shaw DE, Hata A, Jura N. Nat Commun 12 4950 (2021)
  9. Structural Basis of Activin Receptor-Like Kinase 2 (R206H) Inhibition by Bis-heteroaryl Pyrazole-Based Inhibitors for the Treatment of Fibrodysplasia Ossificans Progressiva Identified by the Integration of Ligand-Based and Structure-Based Drug Design Approaches. Sato T, Sekimata K, Sakai N, Watanabe H, Mishima-Tsumagari C, Taguri T, Matsumoto T, Fujii Y, Handa N, Tanaka A, Shirouzu M, Yokoyama S, Hashizume Y, Miyazono K, Koyama H, Honma T. ACS Omega 5 11411-11423 (2020)
  10. Discovery of Novel Pyrazolopyrimidines as Potent, Selective, and Orally Bioavailable Inhibitors of ALK2. Nguyen MH, Atasoylu O, Wu L, Kapilashrami K, Pusey M, Gallagher K, Lai CT, Zhao P, Barbosa J, Liu K, He C, Zhang C, Styduhar ED, Witten MR, Chen Y, Lin L, Yang YO, Covington M, Diamond S, Yeleswaram S, Yao W. ACS Med Chem Lett 13 1159-1164 (2022)


Reviews citing this publication (37)

  1. Bone Morphogenetic Proteins. Katagiri T, Watabe T. Cold Spring Harb Perspect Biol 8 a021899 (2016)
  2. Immunoregulation by members of the TGFβ superfamily. Chen W, Ten Dijke P. Nat Rev Immunol 16 723-740 (2016)
  3. BMP signalling: agony and antagony in the family. Brazil DP, Church RH, Surae S, Godson C, Martin F. Trends Cell Biol 25 249-264 (2015)
  4. Targeting BMP signalling in cardiovascular disease and anaemia. Morrell NW, Bloch DB, ten Dijke P, Goumans MJ, Hata A, Smith J, Yu PB, Bloch KD. Nat Rev Cardiol 13 106-120 (2016)
  5. Transforming Growth Factor β Superfamily Signaling in Development of Colorectal Cancer. Jung B, Staudacher JJ, Beauchamp D. Gastroenterology 152 36-52 (2017)
  6. Bone morphogenetic protein signaling in bone homeostasis. Sánchez-Duffhues G, Hiepen C, Knaus P, Ten Dijke P. Bone 80 43-59 (2015)
  7. The Dual Role of Bone Morphogenetic Proteins in Cancer. Bach DH, Park HJ, Lee SK. Mol Ther Oncolytics 8 1-13 (2018)
  8. The zebrafish as a tool to identify novel therapies for human cardiovascular disease. Asnani A, Peterson RT. Dis Model Mech 7 763-767 (2014)
  9. ACVR1 mutations in DIPG: lessons learned from FOP. Taylor KR, Vinci M, Bullock AN, Jones C. Cancer Res 74 4565-4570 (2014)
  10. Bone morphogenetic proteins and their antagonists: current and emerging clinical uses. Ali IH, Brazil DP. Br J Pharmacol 171 3620-3632 (2014)
  11. The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva. Alessi Wolken DM, Idone V, Hatsell SJ, Yu PB, Economides AN. Bone 109 210-217 (2018)
  12. Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders. Pacifici M, Shore EM. Cytokine Growth Factor Rev 27 93-104 (2016)
  13. Bone Morphogenetic Protein-Based Therapeutic Approaches. Lowery JW, Rosen V. Cold Spring Harb Perspect Biol 10 a022327 (2018)
  14. Towards Multi-Organoid Systems for Drug Screening Applications. Miranda CC, Fernandes TG, Diogo MM, Cabral JMS. Bioengineering (Basel) 5 E49 (2018)
  15. Emerging roles of the bone morphogenetic protein pathway in cancer: potential therapeutic target for kinase inhibition. Jiramongkolchai P, Owens P, Hong CC. Biochem Soc Trans 44 1117-1134 (2016)
  16. Strategies for exploring TGF-β signaling in Drosophila. Peterson AJ, O'Connor MB. Methods 68 183-193 (2014)
  17. Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva. Wentworth KL, Masharani U, Hsiao EC. Br J Clin Pharmacol 85 1180-1187 (2019)
  18. Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2. Williams E, Bullock AN. Bone 109 251-258 (2018)
  19. The Horizon of a Therapy for Rare Genetic Diseases: A "Druggable" Future for Fibrodysplasia Ossificans Progressiva. Cappato S, Giacopelli F, Ravazzolo R, Bocciardi R. Int J Mol Sci 19 E989 (2018)
  20. Structural biology of the TGFβ family. Goebel EJ, Hart KN, McCoy JC, Thompson TB. Exp Biol Med (Maywood) 244 1530-1546 (2019)
  21. Heterotopic bone induction via BMP signaling: Potential therapeutic targets for fibrodysplasia ossificans progressiva. Katagiri T, Tsukamoto S, Kuratani M. Bone 109 241-250 (2018)
  22. Structural perspective of BMP ligands and signaling. Gipson GR, Goebel EJ, Hart KN, Kappes EC, Kattamuri C, McCoy JC, Thompson TB. Bone 140 115549 (2020)
  23. Targeting Epigenetic Pathways in the Treatment of Pediatric Diffuse (High Grade) Gliomas. Vanan MI, Underhill DA, Eisenstat DD. Neurotherapeutics 14 274-283 (2017)
  24. An overview on small molecule-induced differentiation of mesenchymal stem cells into beta cells for diabetic therapy. Pavathuparambil Abdul Manaph N, Sivanathan KN, Nitschke J, Zhou XF, Coates PT, Drogemuller CJ. Stem Cell Res Ther 10 293 (2019)
  25. Design Principles for Pluripotent Stem Cell-Derived Organoid Engineering. Silva TP, Cotovio JP, Bekman E, Carmo-Fonseca M, Cabral JMS, Fernandes TG. Stem Cells Int 2019 4508470 (2019)
  26. Recent Topics in Fibrodysplasia Ossificans Progressiva. Katagiri T, Tsukamoto S, Nakachi Y, Kuratani M. Endocrinol Metab (Seoul) 33 331-338 (2018)
  27. Acquired and congenital forms of heterotopic ossification: new pathogenic insights and therapeutic opportunities. Pacifici M. Curr Opin Pharmacol 40 51-58 (2018)
  28. Management of diffuse intrinsic pontine glioma in children: current and future strategies for improving prognosis. Kaye EC, Baker JN, Broniscer A. CNS Oncol 3 421-431 (2014)
  29. Modeling Polyglutamine Expansion Diseases with Induced Pluripotent Stem Cells. Naphade S, Tshilenge KT, Ellerby LM. Neurotherapeutics 16 979-998 (2019)
  30. Pathogenesis and Clinical Management of Mesenteric Fibrosis in Small Intestinal Neuroendocine Neoplasms: A Systematic Review. Koumarianou A, Alexandraki KI, Wallin G, Kaltsas G, Daskalakis K. J Clin Med 9 E1777 (2020)
  31. A Survey of Strategies to Modulate the Bone Morphogenetic Protein Signaling Pathway: Current and Future Perspectives. Lowery JW, Brookshire B, Rosen V. Stem Cells Int 2016 7290686 (2016)
  32. Fibrodysplasia ossificans progressiva: current concepts from bench to bedside. Kaliya-Perumal AK, Carney TJ, Ingham PW. Dis Model Mech 13 dmm046441 (2020)
  33. Recent Advances in ALK2 Inhibitors. Rooney L, Jones C. ACS Omega 6 20729-20734 (2021)
  34. Approaches toward improving the prognosis of pediatric patients with glioma: pursuing mutant drug targets with emerging small molecules. Snape TJ, Warr T. Semin Pediatr Neurol 22 28-34 (2015)
  35. Fostering open collaboration in drug development for paediatric brain tumours. Wong JF, Brown EJ, Williams E, Bullock AN. Biochem Soc Trans 47 1471-1479 (2019)
  36. Navigating the Complex Landscape of Fibrodysplasia Ossificans Progressiva: From Current Paradigms to Therapeutic Frontiers. Anwar S, Yokota T. Genes (Basel) 14 2162 (2023)
  37. Small-Molecule Probes as Pharmacological Tools for the Bone Morphogenetic Protein Signaling Pathway. Riege D, Herschel S, Fenkl T, Schade D. ACS Pharmacol Transl Sci 6 1574-1599 (2023)

Articles citing this publication (93)

  1. Bone Morphogenetic Protein (BMP) signaling in development and human diseases. Wang RN, Green J, Wang Z, Deng Y, Qiao M, Peabody M, Zhang Q, Ye J, Yan Z, Denduluri S, Idowu O, Li M, Shen C, Hu A, Haydon RC, Kang R, Mok J, Lee MJ, Luu HL, Shi LL. Genes Dis 1 87-105 (2014)
  2. TNFα drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling. Hurst LA, Dunmore BJ, Long L, Crosby A, Al-Lamki R, Deighton J, Southwood M, Yang X, Nikolic MZ, Herrera B, Inman GJ, Bradley JR, Rana AA, Upton PD, Morrell NW. Nat Commun 8 14079 (2017)
  3. Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva. Hino K, Horigome K, Nishio M, Komura S, Nagata S, Zhao C, Jin Y, Kawakami K, Yamada Y, Ohta A, Toguchida J, Ikeya M. J Clin Invest 127 3339-3352 (2017)
  4. Treatment of heterotopic ossification through remote ATP hydrolysis. Peterson JR, De La Rosa S, Eboda O, Cilwa KE, Agarwal S, Buchman SR, Cederna PS, Xi C, Morris MD, Herndon DN, Xiao W, Tompkins RG, Krebsbach PH, Wang SC, Levi B. Sci Transl Med 6 255ra132 (2014)
  5. Enhanced Stem Cell Differentiation and Immunopurification of Genome Engineered Human Retinal Ganglion Cells. Sluch VM, Chamling X, Liu MM, Berlinicke CA, Cheng J, Mitchell KL, Welsbie DS, Zack DJ. Stem Cells Transl Med 6 1972-1986 (2017)
  6. Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. Mohedas AH, Wang Y, Sanvitale CE, Canning P, Choi S, Xing X, Bullock AN, Cuny GD, Yu PB. J Med Chem 57 7900-7915 (2014)
  7. BMPR2 acts as a gatekeeper to protect endothelial cells from increased TGFβ responses and altered cell mechanics. Hiepen C, Jatzlau J, Hildebrandt S, Kampfrath B, Goktas M, Murgai A, Cuellar Camacho JL, Haag R, Ruppert C, Sengle G, Cavalcanti-Adam EA, Blank KG, Knaus P. PLoS Biol 17 e3000557 (2019)
  8. VE-cadherin facilitates BMP-induced endothelial cell permeability and signaling. Benn A, Bredow C, Casanova I, Vukičević S, Knaus P. J Cell Sci 129 206-218 (2016)
  9. ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma. Carvalho D, Taylor KR, Olaciregui NG, Molinari V, Clarke M, Mackay A, Ruddle R, Henley A, Valenti M, Hayes A, Brandon AH, Eccles SA, Raynaud F, Boudhar A, Monje M, Popov S, Moore AS, Mora J, Cruz O, Vinci M, Brennan PE, Bullock AN, Carcaboso AM, Jones C. Commun Biol 2 156 (2019)
  10. Hair follicle stem cell cultures reveal self-organizing plasticity of stem cells and their progeny. Chacón-Martínez CA, Klose M, Niemann C, Glauche I, Wickström SA. EMBO J 36 151-164 (2017)
  11. Role of bone morphogenetic proteins in sprouting angiogenesis: differential BMP receptor-dependent signaling pathways balance stalk vs. tip cell competence. Benn A, Hiepen C, Osterland M, Schütte C, Zwijsen A, Knaus P. FASEB J 31 4720-4733 (2017)
  12. A bone to pick with zebrafish. Mackay EW, Apschner A, Schulte-Merker S. Bonekey Rep 2 445 (2013)
  13. BMP Antagonist Gremlin 2 Limits Inflammation After Myocardial Infarction. Sanders LN, Schoenhard JA, Saleh MA, Mukherjee A, Ryzhov S, McMaster WG, Nolan K, Gumina RJ, Thompson TB, Magnuson MA, Harrison DG, Hatzopoulos AK. Circ Res 119 434-449 (2016)
  14. TGFβ1-induced SMAD2/3 and SMAD1/5 phosphorylation are both ALK5-kinase-dependent in primary chondrocytes and mediated by TAK1 kinase activity. van Caam A, Madej W, Garcia de Vinuesa A, Goumans MJ, Ten Dijke P, Blaney Davidson E, van der Kraan P. Arthritis Res Ther 19 112 (2017)
  15. Small molecules dorsomorphin and LDN-193189 inhibit myostatin/GDF8 signaling and promote functional myoblast differentiation. Horbelt D, Boergermann JH, Chaikuad A, Alfano I, Williams E, Lukonin I, Timmel T, Bullock AN, Knaus P. J Biol Chem 290 3390-3404 (2015)
  16. Risk factors for the development of heterotopic ossification in seriously burned adults: A National Institute on Disability, Independent Living and Rehabilitation Research burn model system database analysis. Levi B, Jayakumar P, Giladi A, Jupiter JB, Ring DC, Kowalske K, Gibran NS, Herndon D, Schneider JC, Ryan CM. J Trauma Acute Care Surg 79 870-876 (2015)
  17. An mTOR Signaling Modulator Suppressed Heterotopic Ossification of Fibrodysplasia Ossificans Progressiva. Hino K, Zhao C, Horigome K, Nishio M, Okanishi Y, Nagata S, Komura S, Yamada Y, Toguchida J, Ohta A, Ikeya M. Stem Cell Reports 11 1106-1119 (2018)
  18. BMP9/p38 MAPK is essential for the antiproliferative effect of resveratrol on human colon cancer. Yuan SX, Wang DX, Wu QX, Ren CM, Li Y, Chen QZ, Zeng YH, Shao Y, Yang JQ, Bai Y, Zhang P, Yu Y, Wu K, Sun WJ, He BC. Oncol Rep 35 939-947 (2016)
  19. Expression of RMRP RNA is regulated in chondrocyte hypertrophy and determines chondrogenic differentiation. Steinbusch MMF, Caron MMJ, Surtel DAM, Friedrich F, Lausch E, Pruijn GJM, Verhesen W, Schroen BLM, van Rhijn LW, Zabel B, Welting TJM. Sci Rep 7 6440 (2017)
  20. BMPR2 inhibits activin and BMP signaling via wild-type ALK2. Olsen OE, Sankar M, Elsaadi S, Hella H, Buene G, Darvekar SR, Misund K, Katagiri T, Knaus P, Holien T. J Cell Sci 131 jcs213512 (2018)
  21. Management of high-grade gliomas in the pediatric patient: Past, present, and future. Vanan MI, Eisenstat DD. Neurooncol Pract 1 145-157 (2014)
  22. Activins as Dual Specificity TGF-β Family Molecules: SMAD-Activation via Activin- and BMP-Type 1 Receptors. Olsen OE, Hella H, Elsaadi S, Jacobi C, Martinez-Hackert E, Holien T. Biomolecules 10 E519 (2020)
  23. Clonal hematopoiesis with JAK2V617F promotes pulmonary hypertension with ALK1 upregulation in lung neutrophils. Kimishima Y, Misaka T, Yokokawa T, Wada K, Ueda K, Sugimoto K, Minakawa K, Nakazato K, Ishida T, Oshima M, Koide S, Shide K, Shimoda K, Iwama A, Ikeda K, Takeishi Y. Nat Commun 12 6177 (2021)
  24. GREM1 is required to maintain cellular heterogeneity in pancreatic cancer. Lan L, Evan T, Li H, Hussain A, Ruiz EJ, Zaw Thin M, Ferreira RMM, Ps H, Riising EM, Zen Y, Almagro J, Ng KW, Soro-Barrio P, Nelson J, Koifman G, Carvalho J, Nye EL, He Y, Zhang C, Sadanandam A, Behrens A. Nature 607 163-168 (2022)
  25. Regulation of hepcidin expression by inflammation-induced activin B. Kanamori Y, Sugiyama M, Hashimoto O, Murakami M, Matsui T, Funaba M. Sci Rep 6 38702 (2016)
  26. SMAD signaling and redox imbalance cooperate to induce prostate cancer cell dormancy. Bui AT, Laurent F, Havard M, Dautry F, Tchénio T. Cell Cycle 14 1218-1231 (2015)
  27. Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva. Williams E, Bagarova J, Kerr G, Xia DD, Place ES, Dey D, Shen Y, Bocobo GA, Mohedas AH, Huang X, Sanderson PE, Lee A, Zheng W, Economides AN, Smith JC, Yu PB, Bullock AN. JCI Insight 6 95042 (2021)
  28. TMPRSS2:ERG gene fusion variants induce TGF-β signaling and epithelial to mesenchymal transition in human prostate cancer cells. Ratz L, Laible M, Kacprzyk LA, Wittig-Blaich SM, Tolstov Y, Duensing S, Altevogt P, Klauck SM, Sültmann H. Oncotarget 8 25115-25130 (2017)
  29. Transforming Growth Factor β1 (TGF-β1) Activates Hepcidin mRNA Expression in Hepatocytes. Chen S, Feng T, Vujić Spasić M, Altamura S, Breitkopf-Heinlein K, Altenöder J, Weiss TS, Dooley S, Muckenthaler MU. J Biol Chem 291 13160-13174 (2016)
  30. Clinical significance of Gremlin 1 in cervical cancer and its effects on cancer stem cell maintenance. Sato M, Kawana K, Fujimoto A, Yoshida M, Nakamura H, Nishida H, Inoue T, Taguchi A, Takahashi J, Adachi K, Nagasaka K, Matsumoto Y, Wada-Hiraike O, Oda K, Osuga Y, Fujii T. Oncol Rep 35 391-397 (2016)
  31. High-throughput screening for modulators of ACVR1 transcription: discovery of potential therapeutics for fibrodysplasia ossificans progressiva. Cappato S, Tonachini L, Giacopelli F, Tirone M, Galietta LJ, Sormani M, Giovenzana A, Spinelli AE, Canciani B, Brunelli S, Ravazzolo R, Bocciardi R. Dis Model Mech 9 685-696 (2016)
  32. Transcriptome and proteome characterization of surface ectoderm cells differentiated from human iPSCs. Qu Y, Zhou B, Yang W, Han B, Yu-Rice Y, Gao B, Johnson J, Svendsen CN, Freeman MR, Giuliano AE, Sareen D, Cui X. Sci Rep 6 32007 (2016)
  33. Bone morphogenetic protein 2 is a depot-specific regulator of human adipogenesis. Denton NF, Eghleilib M, Al-Sharifi S, Todorčević M, Neville MJ, Loh N, Drakesmith A, Karpe F, Pinnick KE. Int J Obes (Lond) 43 2458-2468 (2019)
  34. Comparison of newly developed anti-bone morphogenetic protein 4 llama-derived antibodies with commercially available BMP4 inhibitors. Calpe S, Correia AC, Sancho-Serra Mdel C, Krishnadath KK. MAbs 8 678-688 (2016)
  35. Coordinated Proliferation and Differentiation of Human-Induced Pluripotent Stem Cell-Derived Cardiac Progenitor Cells Depend on Bone Morphogenetic Protein Signaling Regulation by GREMLIN 2. Bylund JB, Trinh LT, Awgulewitsch CP, Paik DT, Jetter C, Jha R, Zhang J, Nolan K, Xu C, Thompson TB, Kamp TJ, Hatzopoulos AK. Stem Cells Dev 26 678-693 (2017)
  36. A role for BMP-induced homeobox gene MIXL1 in acute myelogenous leukemia and identification of type I BMP receptor as a potential target for therapy. Raymond A, Liu B, Liang H, Wei C, Guindani M, Lu Y, Liang S, St John LS, Molldrem J, Nagarajan L. Oncotarget 5 12675-12693 (2014)
  37. BMP Signaling Regulates Bone Morphogenesis in Zebrafish through Promoting Osteoblast Function as Assessed by Their Nitric Oxide Production. Windhausen T, Squifflet S, Renn J, Muller M. Molecules 20 7586-7601 (2015)
  38. Regulation of stem/progenitor cell maintenance by BMP5 in prostate homeostasis and cancer initiation. Tremblay M, Viala S, Shafer ME, Graham-Paquin AL, Liu C, Bouchard M. Elife 9 e54542 (2020)
  39. Shared ACVR1 mutations in FOP and DIPG: Opportunities and challenges in extending biological and clinical implications across rare diseases. Han HJ, Jain P, Resnick AC. Bone 109 91-100 (2018)
  40. Letter Transforming growth factor β-inhibitor Repsox downregulates collagen expression of scleroderma dermal fibroblasts and prevents bleomycin-induced mice skin fibrosis. Ide M, Jinnin M, Tomizawa Y, Wang Z, Kajihara I, Fukushima S, Hashizume Y, Asano Y, Ihn H. Exp Dermatol 26 1139-1143 (2017)
  41. Open access target validation is a more efficient way to accelerate drug discovery. Lee WH. PLoS Biol 13 e1002164 (2015)
  42. Temperature and insulin signaling regulate body size in Hydra by the Wnt and TGF-beta pathways. Mortzfeld BM, Taubenheim J, Klimovich AV, Fraune S, Rosenstiel P, Bosch TCG. Nat Commun 10 3257 (2019)
  43. Rac1 promotes chondrogenesis by regulating STAT3 signaling pathway. Kim H, Sonn JK. Cell Biol Int 40 976-983 (2016)
  44. ACVR1-Fc suppresses BMP signaling and chondro-osseous differentiation in an in vitro model of Fibrodysplasia ossificans progressiva. Pang J, Zuo Y, Chen Y, Song L, Zhu Q, Yu J, Shan C, Cai Z, Hao J, Kaplan FS, Shore EM, Zhang K. Bone 92 29-36 (2016)
  45. Bone morphogenetic protein signaling is required for RAD51-mediated maintenance of genome integrity in vascular endothelial cells. Vattulainen-Collanus S, Southwood M, Yang XD, Moore S, Ghatpande P, Morrell NW, Lagna G, Hata A. Commun Biol 1 149 (2018)
  46. FRAGSITE: A Fragment-Based Approach for Virtual Ligand Screening. Zhou H, Cao H, Skolnick J. J Chem Inf Model 61 2074-2089 (2021)
  47. Lung gene expression signatures suggest pathogenic links and molecular markers for pulmonary tuberculosis, adenocarcinoma and sarcoidosis. Chai Q, Lu Z, Liu Z, Zhong Y, Zhang F, Qiu C, Li B, Wang J, Zhang L, Pang Y, Liu CH. Commun Biol 3 604 (2020)
  48. Tbx20 Induction Promotes Zebrafish Heart Regeneration by Inducing Cardiomyocyte Dedifferentiation and Endocardial Expansion. Fang Y, Lai KS, She P, Sun J, Tao W, Zhong TP. Front Cell Dev Biol 8 738 (2020)
  49. Transient exposure to androgens induces a remarkable self-sustained quiescent state in dispersed prostate cancer cells. Bui AT, Huang ME, Havard M, Laurent-Tchenio F, Dautry F, Tchenio T. Cell Cycle 16 879-893 (2017)
  50. A Tribolium castaneum whole-embryo culture protocol for studying the molecular mechanisms and morphogenetic movements involved in insect development. Macaya CC, Saavedra PE, Cepeda RE, Nuñez VA, Sarrazin AF. Dev Genes Evol 226 53-61 (2016)
  51. Bone morphogenetic protein signaling in rotator cuff muscle atrophy and fatty infiltration. Liu X, Joshi S, Ravishankar B, Laron D, Kim HT, Feeley BT. Muscles Ligaments Tendons J 5 113-119 (2015)
  52. Chronic myeloid leukaemia cells require the bone morphogenic protein pathway for cell cycle progression and self-renewal. Toofan P, Busch C, Morrison H, O'Brien S, Jørgensen H, Copland M, Wheadon H. Cell Death Dis 9 927 (2018)
  53. Novel Quinazolinone Inhibitors of ALK2 Flip between Alternate Binding Modes: Structure-Activity Relationship, Structural Characterization, Kinase Profiling, and Cellular Proof of Concept. Hudson L, Mui J, Vázquez S, Carvalho DM, Williams E, Jones C, Bullock AN, Hoelder S. J Med Chem 61 7261-7272 (2018)
  54. Optogenetic Control of the BMP Signaling Pathway. Humphreys PA, Woods S, Smith CA, Bates N, Cain SA, Lucas R, Kimber SJ. ACS Synth Biol 9 3067-3078 (2020)
  55. Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma. Ensan D, Smil D, Zepeda-Velázquez CA, Panagopoulos D, Wong JF, Williams EP, Adamson R, Bullock AN, Kiyota T, Aman A, Roberts OG, Edwards AM, O'Meara JA, Isaac MB, Al-Awar R. J Med Chem 63 4978-4996 (2020)
  56. A BMPR2/YY1 Signaling Axis Is Required for Human Cytomegalovirus Latency in Undifferentiated Myeloid Cells. Poole E, Carlan da Silva MC, Huang C, Perera M, Jackson S, Groves IJ, Wills M, Rana A, Sinclair J. mBio 12 e0022721 (2021)
  57. Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors. Jiang JK, Huang X, Shamim K, Patel PR, Lee A, Wang AQ, Nguyen K, Tawa G, Cuny GD, Yu PB, Zheng W, Xu X, Sanderson P, Huang W. Bioorg Med Chem Lett 28 3356-3362 (2018)
  58. Identification and characterization of regulatory elements in the promoter of ACVR1, the gene mutated in Fibrodysplasia Ossificans Progressiva. Giacopelli F, Cappato S, Tonachini L, Mura M, Di Lascio S, Fornasari D, Ravazzolo R, Bocciardi R. Orphanet J Rare Dis 8 145 (2013)
  59. Receptor-interacting protein kinase 2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffold. Suebsuwong C, Dai B, Pinkas DM, Duddupudi AL, Li L, Bufton JC, Schlicher L, Gyrd-Hansen M, Hu M, Bullock AN, Degterev A, Cuny GD. Eur J Med Chem 200 112417 (2020)
  60. Comment Towards a cure for Fibrodysplasia ossificans progressiva. Sanchez-Duffhues G, de Gorter DJ, Ten Dijke P. Ann Transl Med 4 S28 (2016)
  61. Biemamides A-E, Inhibitors of the TGF-β Pathway That Block the Epithelial to Mesenchymal Transition. Zhang F, Braun DR, Ananiev GE, Hoffmann FM, Tsai IW, Rajski SR, Bugni TS. Org Lett 20 5529-5532 (2018)
  62. Deficiency of TMEM53 causes a previously unknown sclerosing bone disorder by dysregulation of BMP-SMAD signaling. Guo L, Iida A, Bhavani GS, Gowrishankar K, Wang Z, Xue JY, Wang J, Miyake N, Matsumoto N, Hasegawa T, Iizuka Y, Matsuda M, Nakashima T, Takechi M, Iseki S, Yambe S, Nishimura G, Koseki H, Shukunami C, Girisha KM, Ikegawa S. Nat Commun 12 2046 (2021)
  63. Hypoxia-selective allosteric destabilization of activin receptor-like kinases: A potential therapeutic avenue for prophylaxis of heterotopic ossification. Lu G, Tandang-Silvas MR, Dawson AC, Dawson TJ, Groppe JC. Bone 112 71-89 (2018)
  64. Inhibition of bone morphogenetic proteins signaling suppresses metastasis melanoma: a proteomics approach. Kalal BS, Modi PK, Upadhya D, Saha P, Prasad TSK, Pai VR. Am J Transl Res 13 11081-11093 (2021)
  65. Role of bone morphogenetic protein signaling in bovine early embryonic development and stage specific embryotropic actions of follistatin†. Rajput SK, Yang C, Ashry M, Folger JK, Knott JG, Smith GW. Biol Reprod 102 795-805 (2020)
  66. A Small Dibromotyrosine Derivative Purified From Pseudoceratina Sp. Suppresses TGF-β Responsiveness by Inhibiting TGF-β Type I Receptor Serine/Threonine Kinase Activity. Chen CL, Kao YC, Yang PH, Sung PJ, Wen ZH, Chen JJ, Huang YB, Chen PY. J Cell Biochem 117 2800-2814 (2016)
  67. Differential kinase activity of ACVR1 G328V and R206H mutations with implications to possible TβRI cross-talk in diffuse intrinsic pontine glioma. Cao H, Jin M, Gao M, Zhou H, Tao YJ, Skolnick J. Sci Rep 10 6140 (2020)
  68. Bone morphogenetic protein type I receptor inhibition induces cleft palate associated with micrognathia and cleft lower lip in mice. Lai Y, Xie C, Zhang S, Gan G, Wu D, Chen W. Birth Defects Res A Clin Mol Teratol 106 612-623 (2016)
  69. Cercosporamide inhibits bone morphogenetic protein receptor type I kinase activity in zebrafish. Hoeksma J, van der Zon GCM, Ten Dijke P, den Hertog J. Dis Model Mech 13 dmm045971 (2020)
  70. Establishment of a novel model of chondrogenesis using murine embryonic stem cells carrying fibrodysplasia ossificans progressiva-associated mutant ALK2. Fujimoto M, Ohte S, Shin M, Yoneyama K, Osawa K, Miyamoto A, Tsukamoto S, Mizuta T, Kokabu S, Machiya A, Okuda A, Suda N, Katagiri T. Biochem Biophys Res Commun 455 347-352 (2014)
  71. Local modulation of the Wnt/β-catenin and bone morphogenic protein (BMP) pathways recapitulates rib defects analogous to cerebro-costo-mandibular syndrome. Turner BRH, Itasaki N. J Anat 236 931-945 (2020)
  72. MicroRNA26 attenuates vascular smooth muscle maturation via endothelial BMP signalling. Watterston C, Zeng L, Onabadejo A, Childs SJ. PLoS Genet 15 e1008163 (2019)
  73. Novel venom-based peptides (P13 and its derivative-M6) to maintain self-renewal of human embryonic stem cells by activating FGF and TGFβ signaling pathways. Ma R, Ren Z, Li B, Siu SWI, Chen G, Kwok HF. Stem Cell Res Ther 11 243 (2020)
  74. Pharmacologic Strategies for Assaying BMP Signaling Function. Dinter T, Bocobo GA, Yu PB. Methods Mol Biol 1891 221-233 (2019)
  75. Vitamin B1 Supports the Differentiation of T Cells through TGF-β Superfamily Production in Thymic Stromal Cells. Hirata SI, Sawane K, Adachi J, Isoyama J, Sugiura Y, Matsunaga A, Hosomi K, Tomonaga T, Suematsu M, Nagatake T, Kunisawa J. iScience 23 101426 (2020)
  76. 15-Lipoxygenase promotes chronic hypoxia-induced phenotype changes of PASMCs via positive feedback-loop of BMP4. Yu X, Wei L, Lu P, Shen T, Liu X, Li T, Zhang B, Yu H, Zhu D. J Cell Physiol 230 1489-1502 (2015)
  77. Sox7 Regulates Lineage Decisions in Cardiovascular Progenitor Cells. Doyle MJ, Magli A, Estharabadi N, Amundsen D, Mills LJ, Martin CM. Stem Cells Dev 28 1089-1103 (2019)
  78. A catalyst- and solvent-free thermal multicomponent approach for the construction of diverse and polysubstituted 2-aminopyridines and their antibacterial activity. Baral ER, Sharma K, Akhtar MS, Lee YR. Org Biomol Chem 14 10285-10297 (2016)
  79. Discovery, synthesis and characterization of a series of 7-aryl-imidazo[1,2-a]pyridine-3-ylquinolines as activin-like kinase (ALK) inhibitors. Engers DW, Bollinger SR, Felts AS, Vadukoot AK, Williams CH, Blobaum AL, Lindsley CW, Hong CC, Hopkins CR. Bioorg Med Chem Lett 30 127418 (2020)
  80. Influencing the Fate of Cardiac and Neural Stem Cell Differentiation Using Small Molecule Inhibitors of ALK5. Zhong Q, Laco F, Liao MC, Woo TL, Oh SKW, Chai CLL. Stem Cells Transl Med 7 709-720 (2018)
  81. Shear Stress Alterations Activate BMP4/pSMAD5 Signaling and Induce Endothelial Mesenchymal Transition in Varicose Veins. Chandran Latha K, Sreekumar A, Beena V, S S BR, Lakkappa RB, Kalyani R, Nair R, Kalpana SR, Kartha CC, Surendran S. Cells 10 3563 (2021)
  82. TXNIP Suppresses the Osteochondrogenic Switch of Vascular Smooth Muscle Cells in Atherosclerosis. Woo SH, Kyung D, Lee SH, Park KS, Kim M, Kim K, Kwon HJ, Won YS, Choi I, Park YJ, Go DM, Oh JS, Yoon WK, Paik SS, Kim JH, Kim YH, Choi JH, Kim DY. Circ Res 132 52-71 (2023)
  83. Apyrase as a novel therapeutic inhibitor of heterotopic ossification. Liang OD, Reginato AM, Medici D. Ann Transl Med 3 S32 (2015)
  84. Automated Hypothesis Generation to Identify Signals Relevant in the Development of Mammalian Cell and Tissue Bioprocesses, With Validation in a Retinal Culture System. Toms D, Al-Ani A, Sunba S, Tong QYV, Workentine M, Ungrin M. Front Bioeng Biotechnol 8 534 (2020)
  85. Blockade of Activin Receptor IIB Protects Arthritis Pathogenesis by Non-Amplification of Activin A-ACVR2B-NOX4 Axis Pathway. Jeon J, Lee H, Jeon MS, Kim SJ, Choi C, Kim KW, Yang DJ, Lee S, Bae YS, Choi WI, Jung J, Eyun SI, Yang S. Adv Sci (Weinh) 10 e2205161 (2023)
  86. Design of pyrido[2,3-d]pyrimidin-7-one inhibitors of receptor interacting protein kinase-2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling. Nikhar S, Siokas I, Schlicher L, Lee S, Gyrd-Hansen M, Degterev A, Cuny GD. Eur J Med Chem 215 113252 (2021)
  87. Differences in the intrinsic chondrogenic potential of human mesenchymal stromal cells and iPSC-derived multipotent cells. Xiang S, Lin Z, Makarcyzk MJ, Riewruja K, Zhang Y, Zhang X, Li Z, Clark KL, Li E, Liu S, Hao T, Fritch MR, Alexander PG, Lin H. Clin Transl Med 12 e1112 (2022)
  88. New Financial and Research Models for Pediatric Orphan Drug Development - Focus on the NCATS TRND Program. Shen J, Grewal G, Pilon AM, McKew JC. Pharmaceut Med 28 1-6 (2014)
  89. A blocking monoclonal antibody reveals dimerization of intracellular domains of ALK2 associated with genetic disorders. Katagiri T, Tsukamoto S, Kuratani M, Tsuji S, Nakamura K, Ohte S, Kawaguchi Y, Takaishi K. Nat Commun 14 2960 (2023)
  90. Differentiation of human induced pluripotent stem cells into cortical neural stem cells. Neaverson A, Andersson MHL, Arshad OA, Foulser L, Goodwin-Trotman M, Hunter A, Newman B, Patel M, Roth C, Thwaites T, Kilpinen H, Hurles ME, Day A, Gerety SS. Front Cell Dev Biol 10 1023340 (2022)
  91. FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells. Quist-Løkken I, Andersson-Rusch C, Kastnes MH, Kolos JM, Jatzlau J, Hella H, Olsen OE, Sundan A, Knaus P, Hausch F, Holien T. Cell Commun Signal 21 25 (2023)
  92. Identification of small molecule inhibitors of ALK2: a virtual screening, density functional theory, and molecular dynamics simulations study. Kausar T, Nayeem SM. J Mol Model 24 262 (2018)
  93. Screens in aging-relevant human ALS-motor neurons identify MAP4Ks as therapeutic targets for the disease. Liu ML, Ma S, Tai W, Zhong X, Ni H, Zou Y, Wang J, Zhang CL. Cell Death Dis 15 4 (2024)